 Craig-Hallum analyst Jason Kreyer lowered the price target on Cardlytics Inc NASDAQ: CDLX to 100 from 120, implying a 25.4 upside, and reiterated a Buy. While broader macro concerns over supply chain issues and corresponding labor shortages have been widely topical over the past month, Cardlytics cited these headwinds a quarter ago, reset expectations, and is now working through this new paradigm, the analyst contends. 